Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY – Get Free Report) was the recipient of a significant decrease in short interest in the month of April. As of April 30th, there was short interest totaling 2,682 shares, a decrease of 60.7% from the April 15th total of 6,831 shares. Currently, 0.0% of the company’s shares are sold short. Based on an average daily volume of 87,964 shares, the days-to-cover ratio is presently 0.0 days.
Santen Pharmaceutical Stock Performance
Shares of OTCMKTS SNPHY traded down $0.16 during midday trading on Friday, hitting $11.74. 740 shares of the company traded hands, compared to its average volume of 15,511. Santen Pharmaceutical has a 12-month low of $9.22 and a 12-month high of $12.68. The firm has a market cap of $3.78 billion and a P/E ratio of 0.10. The stock has a 50-day moving average price of $10.93 and a 200 day moving average price of $10.72.
Wall Street Analyst Weigh In
Separately, Zacks Research raised Santen Pharmaceutical to a “hold” rating in a research note on Monday, April 13th. One analyst has rated the stock with a Hold rating, According to MarketBeat, the stock has a consensus rating of “Hold”.
Santen Pharmaceutical Company Profile
Santen Pharmaceutical Co, Ltd. is a Japan‐based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over‐the‐counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post‐operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.
With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.
Further Reading
- Five stocks we like better than Santen Pharmaceutical
- 3 Crucial Aerospace Component Makers That Analysts Love
- Alphabet’s Googlebook Brings Gemini AI to PC Hardware
- Peloton Stock Gives Back Gains After Upbeat Earnings Report
- MarketBeat Week in Review – 05/11 – 05/15
Receive News & Ratings for Santen Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Santen Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
-STRC){kind=small}
